ID   UT-SCC-1B
AC   CVCL_7819
SY   University of Turku-Squamous Cell Carcinoma-1B
DR   cancercelllines; CVCL_7819
DR   GEO; GSM901092
DR   Wikidata; Q54992081
RX   DOI=10.1158/1538-7445.AM2020-507;
RX   PubMed=8725545;
RX   PubMed=8782485;
RX   PubMed=17312569;
RX   PubMed=30135316;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Oral cavity, gingiva; UBERON=UBERON_0001828.
ST   Source(s): PubMed=30135316
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,10
ST   D16S539: 11
ST   D18S51: 16
ST   D19S433: 15
ST   D21S11: 29,31
ST   D2S1338: 25
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 8,9
ST   D8S1179: 10,11
ST   FGA: 22,24
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 15,17
DI   NCIt; C129857; Gingival squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7818 ! UT-SCC-1A
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 15
//
RX   DOI=10.1158/1538-7445.AM2020-507;
RA   Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J.,
RA   Koritzinsky M., Wouters B.G.;
RT   "Repurposing of FDA approved drugs for treatment of metastatic HNSCC.";
RL   Cancer Res. 80 Suppl. 16:507-507(2020).
//
RX   PubMed=8725545; DOI=10.3109/00016489609137854;
RA   Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.;
RT   "Increased radiosensitivity is associated with p53 mutations in cell
RT   lines derived from oral cavity carcinoma.";
RL   Acta Oto-Laryngol. 116:341-344(1996).
//
RX   PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x;
RA   Servomaa K., Kiuru A., Grenman R., Pekkola-Heino K., Pulkkinen J.O.,
RA   Rytomaa T.;
RT   "p53 mutations associated with increased sensitivity to ionizing
RT   radiation in human head and neck cancer cell lines.";
RL   Cell Prolif. 29:219-230(1996).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//